-transparent.png){kind=logo}
Thirty-nine patients with gynecological malignancies who had failed on conventional chemotherapeutic agents were treated with Leo 1031 to study the effective dosage and toxicity of the compound in gynecological malignancies. Six patients with ovarian adenocarcinoma were also treated subsequently by using this compound as primary therapy. Comparable results (33% response rate) were obtained with excellent subjective response rate) were obtained with excellent subjective response and minimal hematologic toxicity. Leo 1031 given 30 mg per day was well tolerated by most of the patients but increasing the dose to 40 mg per day led to development of severe hematologic toxicity with no change in response rate. No patients developed clinical evidence of steroid toxicity.
S B Lele, and
M S Piver, and
J J Barlow, and
G P Murphy
January 1978,
Cancer,
S B Lele, and
M S Piver, and
J J Barlow, and
G P Murphy
March 1976,
Cancer treatment reports,
S B Lele, and
M S Piver, and
J J Barlow, and
G P Murphy
November 1979,
Scandinavian journal of haematology,
S B Lele, and
M S Piver, and
J J Barlow, and
G P Murphy
January 1975,
Journal of surgical oncology,
S B Lele, and
M S Piver, and
J J Barlow, and
G P Murphy
July 1980,
Cancer,
S B Lele, and
M S Piver, and
J J Barlow, and
G P Murphy
January 1980,
Acta medica Scandinavica,
S B Lele, and
M S Piver, and
J J Barlow, and
G P Murphy
January 1977,
Osterreichische Zeitschrift fur Onkologie. Austrian journal of oncology,
S B Lele, and
M S Piver, and
J J Barlow, and
G P Murphy
October 1973,
European journal of cancer,
S B Lele, and
M S Piver, and
J J Barlow, and
G P Murphy
January 1977,
European journal of cancer,
S B Lele, and
M S Piver, and
J J Barlow, and
G P Murphy
March 1979,
Cancer treatment reports,
